Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.3 USD | +1.08% | -4.19% | -32.50% |
May. 21 | Nestle set to sell $5 pizza, sandwiches for Wegovy, Ozempic users | RE |
May. 21 | The latest transactions by star managers |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company does not generate enough profits, which is an alarming weak point.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.50% | 1.03B | B+ | ||
+11.85% | 8.05B | D+ | ||
+5.29% | 7.59B | C- | ||
+2.63% | 6.07B | - | ||
-2.80% | 3.85B | B- | ||
-11.22% | 3.55B | D | ||
-7.04% | 1.28B | - | - | |
+12.52% | 971M | - | ||
-15.69% | 813M | C+ | ||
+2.88% | 731M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLF Stock
- Ratings Herbalife Ltd.